Renibus Therapeutics, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lantana FL United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03630029
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Renibus Therapeutics, Inc. | Renibus Therapuetics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

iron sucrose (venofer) (5 trials)

stannic protoporfin (2 trials)

Drugs in Phase 2 Trials (1)

stannous protoporphyrin (3 trials)

Drugs in Phase 1 Trials (1)

Stannous Protoporpyhrin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 1)

Disease Progression (Phase 2)

Kidney Diseases (Phase 1)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4